Tenax Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-17.8M | $-15.7M | $-15.5M | $-15.8M | $-10.8M | $-10.4M | $-6.3M | $-4.0M |
| Depreciation & Amortization | — | — | — | — | — | — | $0 | $0 |
| Depreciation | — | — | — | — | — | — | — | $0 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.3M | $2.8M | $4.8M | $5.6M | $4.6M | $4.1M | $970.0K | $14.0K |
| Net Cash from Operating Activities | $-14.2M | $-9.3M | $-13.4M | $-9.2M | $-6.3M | $-7.0M | $-3.5M | $-3.1M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $13.4M | $30.5M | $11.6M | $3.1M | $278.0K | $23.6M | $67.0K | $92.0M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |